Breaking News

Affymax, Takeda Recall Omontys Injection

Postmarketing reports show serious hypersensitivity reactions

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. have voluntarily recalled all lots of OMONTYS (peginesatide) Injection as a result of postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis. The companies have been working with the FDA and issued a letter to health care professionals indicating that no new or existing patients should receive OMONTYS, which is indicated for the treatment of anemia due to chronic kidney disease.   To date, fatal reactions have be...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters